Cell-mediated immunity is critical to host defenses against the fungal infection cryptococcosis. Here, two functions critical to effective cell-mediated immunity (CMI), lymphoproliferation and cytokine release, were studied in Cryptococcus neoformansstimulated peripheral blood mononuclear cells (PBMC) from seven healthy donors (controls) and two patients with cryptococcosis. PBMC responses to C. neoformans were compared with responses to Candida albicans. Control and patient PBMC had significant lymphoproliferation in response to whole C. neoformans, with peak proliferation seen following 8 days of culture, but only patient PBMC proliferated when stimulated with C. neoformans mannoprotein. C. neoformans-stimulated control PBMC released IL-2, IFN-y, and IL-t0 into the supernatant with peak or near peak concentrations of these three cytokines generally seen by day 1. Release of IL-4 was low or undetectable. In contrast, C. neoformans-stimulated patient PBMC released IFN-?, which peaked on day 7, as well as IL-4, IL-10, and in one of two patients, IL-2. Cytokine release occurred later in patient (compared with control) PBMC. Lymphoproliferation and cytokine release were similar comparing control PBMC stimulated with C. neoformans versus Candida albicans. Thus, the magnitude and kinetics of the lymphoproliferative response to whole C, neoformans is similar comparing PBMC from controls and patients, but the cytokine profiles differ. Moreover, the capacity of patient PBMC to respond to soluble mannoprotein lends support to studies of mannoprotein components as vaccine candidates.
Introduction
In the past decade, it has become apparent that for many infectious agents, the nature of the specific immune response is determined by the set of cytokines produced by CD4 + T helper (TH) cells [1] [2] [3] . TH1 cells secrete IFN-y and IL-2 which drive the cell-mediated immunity [4] [5] [6] . C neoformans has a worldwide distribution and exposure to the fungus is presumably common [7] . Nevertheless, it is unknown whether lymphoproliferation stimulated by whole C. neoformans is in fact an amnestic response to past exposure to C. neoformans or a consequence of past exposure to other microorganisms possessing epitopes which cross-react with cryptococcal antigen(s). Evidence for the latter is the finding that PBMC from persons who have recovered from cryptococcosis respond to both whole C. neoformans and a soluble cryptococcal culture filtrate whereas PBMC from healthy donors respond to whole organisms only [4] .
In the experiments reported herein, we further defined the conditions under which human PBMC from normal donors and from patients with cryptococcosis proliferate in response to whole C. neoformans and a soluble mannoprotein fraction derived from C. neoformans. Moreover, we examined the cytokine profile stimulated during the lymphoproliferative response to C. neo/brmans by measuring release of IFN-7, IL-2, IL-4 and IL-10. Finally, we compared the nature of lymphoproliferative and cytokine response to C. neoJormans with that of another medically important fungus, C. albicans.
Materials and methods

Materials
All reagents were obtained from Sigma Chemical Co. (St Louis, MO) unless stated otherwise. All experiments were performed under conditions carefully designed to minimize endotoxin contamination as described [8, 9] . RPM[ 1640 and PBS were obtained from Biowhittaker (Walkersville, MD) and contained less than 0.005 endotoxin units per ml. Pooled human serum (PHS) was prepared by combining serum from greater than ten healthy donors under conditions carefully designed to minimize endotoxin contamination and preserve complement activity. Heat-inactivated PHS (AH-PHS) was prepared by heating PHS to 56 °C for 30 rain. Unless otherwise indicated, medium was RPMI 1640 containing 10% PHS, and all incubations were performed in humidified air supplemented with 5% CO, at 37 °C.
Fungi
Serotype A strain 145 [9] [10] [11] of C. neoformans was grown on Sabouraud glucose agar at 25 °C for 4 days. Under such conditions, capsule thickness averaged 1.2/tm [9] .
Where indicated, C. neoformans was grown on asparagine agar or in RPMI 1640 in the absence of bicarbonate, pH 6.0, as described [9] . A previously characterized isolate of C. albicans [12, 13] [8, 9] .
C. neoformans mannopratein
Mannoprotein derived from C neoformans acapsular strain cap67 (a generous gift of Dr Robert Cherniak, Georgia State University, Atlanta, GA) was purified as described [14, 15] . Briefly, an ultrafiltrate from a culture of cap67 was applied to a column of conconavalin ASepharose 4B. The mannoprotein fraction corresponds to the peak eluted with 0.2 M methyl-a-D-mannopyranoside and consists of 21% protein. Mannoprotein was dialysed, lyophilized, dissolved in PBS and stored in aliquots at -70 °C until use. This fraction was used at a final concentration of 25/~g ml-1.
Peripheral blood mononuclear cells (PBMC)
Human peripheral blood was obtained by venipuncture from normal volunteers recruited through advertisements placed in the medical center (controls) or persons with cryptococcosis (patients). Blood was anticoagulated with heparin and the PBMC purified by centrifugation on a Ficoll Hypaque density gradient [9] .
Lymphocyte proliferation
Lymphocytes (1 x 105) and fungal cells (1 x 105) were co-incubated in 96-well flat-bottom plates (Coming Glass Works, Coming, NY) containing a final volume of 150/11 of medium per cell well [5] . Wells were pulsed with [3H]-thymidine (0.5¢zCuries; Dupont NEN, Boston, MA) during the last 18 h of culture. Plates were harvested after 4, 8 and 11 days of culture with a cell harvester (PHD; Cambridge Technology, Watertown, MA) onto glass filter paper and counted by scintillation spectroscopy. All proliferation assays included negative controls containing PBMC but no fungi and positive controls containing PBMC plus 1 pg of phytohaemagglutanin (PHA) per ml. All donors had vigorous proliferative responses to PHA, with peak responses seen on day 4 (data not shown).
Cytokine release
Lymphocytes (1 x 10 6) and fungal cells (1 x 106) were co-incubated in 24-well flat-bottom plates (Costar; Cambridge, MA) containing a final volume of 1 ml of medium per cell well [5] . Wells containing PBMC alone also were included. After 1, 3 and 7 days of incubation, supernatants were collected and frozen at -70% until cytokine assay.
Cytokine concentrations in cell supernatants were quantitated by ELISA using antibody pairs and standards purchased from Genzyme Corporation (Cambridge, MA) for IFN-7 and PharMingen (San Diego, CA) for IL-4 and IL-10 according to the manufacturer's directions. IL-2 was measured with a commercial kit (BioSource International, Camarillo, CA). All ELISAs were sensitive to 10pgml ~.
Statistics
Means and SE were compared using the two-tailed, two sample t-test on a statistical software program (SigmaStat for Windows, Jandel Scientific Software, San Rafael, CA).
j~/--. 
Results
Optimal conditions for lymphoproliferation
Initial experiments defined the optimal conditions for lymphoproliferation of control PBMC in response to heat-killed C. neoformans and C. albicans. Consistent with previous data [6] , optimal values were found using an equal number (105) of fungi and PBMC per well (data not shown). Both the kinetics and the magnitude of the lymphoproliferative response were similar when comparing autologous serum with PHS (data not shown). Consistent with the known role of complement in monocyte recognition of C neoJbrmans [16] , heat-inactivation of PHS inhibited the lymphoproliferative response to C neoformans from five donors by a mean of 67%
(range = 39-80%; P < 0.001). Lymphoproliferation in response to C. neoformans was similar comparing organisms grown on Sabouraud glucose agar, asparagine agar and RPMI 1640 without bicarbonate (data not shown). Subsequent experiments used fungi grown on Sabouraud glucose agar and opsonized with PHS.
Lymphoproliferation and cytokine profiles in fungal-stimulated normal PBMC
Lymphoproliferation and cytokine release were measured simultaneously in PBMC from seven healthy donors stimulated with C. neoJormans and C. albicans. As expected based on previously published data [4] [5] [6] 17] , the lymphoproliferative response to both stimuli peaked around day 8 ( release was detected, it was transient and at levels < 100 pg ml J. Median values for IL-2, IL-4, IFN-7, and IL-10 were below the limits of detection ( < 10 pg ml-1) in supernatants from PBMC left unstimulated. Additional release of any of the four cytokines was not detected when measured at day l0 of culture (data not shown).
Lymphoproliferation and cytokine release in patients with cryptococcosis
In the final experiment, two patients with cryptococcosis without known immunosuppression (including negative serologies for HIV) were studied. The first patient was a 24-year-old man who presented with a 1 year history of 
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Fig. 2 Cytokine release stimulated by C. neoformans. PBMC from seven donors were stimulated with C. neoformans as described in Materials and methods. Supernatants were collected after 1, 3 and 7 days and assayed for IFN-7, IL-2, IL-10 and |L-4 by ELISA. The lower limit of sensitivity of the ELISAs was 10 pg ml-1. For those situations where cytokine release was less than 10 pg ml-~, values between 5 and 9 pg ml-~ were assigned to facilitate presentation of data.
fevers, cough, weight loss and a cavitary lesion on chest radiographs which failed to respond to antituberculosis and antibacterial therapy. He had a history of heavy exposure to aerosolized pigeon droppings. He was diagnosed with pulmonary cryptococcosis following a lung biopsy. Evaluation for extrapulmonary disease including meningitis was negative. This patient was on oral fluconazole when studied. The second patient was a 65-yearold man without significant past medical history who presented with behavioural changes and syncope. He raised ducks and other birds as a hobby. Work-up revealed cryptococcal meningitis complicated by multiple cerebral and cerebellar cryptococcomas. This patient was receiving amphotericin B and 5-flucytosine when studied.
Immunophenotyping of lymphocytes from patients 1 and 2 were completely within normal limits, including CD4 counts of 824 and 676 cells#m ~. PBMC from both patients responded to whole C. neoformans and the mannoprotein fraction derived from a culture filtrate of an acapsular strain (Fig. 4) . Patient PBMC released modest amounts of IFN-7, which progressively increased over the time course studied, when stimulated with whole heat-killed C. neoformans (Fig. 5) . IL-2 release was detected in only one of the subjects. IL-4 release was seen in PBMC from both patients. Moreover, peak levels of IL-4 were higher than those seen in supernatants from control PBMC stimulated with C. neoformans (as demonstrated on Fig. 2 ). Patient PBMC also released IL-10 when stimulated with C.
neof ormans.
Patient PBMC were also tested for lymphoproliferation and cytokine release following stimulation with whole heat-killed C. albicans. Responses were similar,to that seen with control PBMC. Peak lymphoproliferation was seen on day 8 (data not shown). Cytokine release (pg ml -~) for patient 1 on days 1, 3 and 7 was as follows: IFN-7 release was 1424, 3901 and 3636, respectively; IL-2 was 91, 104 and llSpg m1-1, respectively; IL-10 was 4095, 1492 and 735 pg ml-~, respectively; and IL-4 was undetectable at three time points. Cytokine release (pg ml-I) for patient 2 on days 1, 3 and 7 was as follows: IFN-7 release was < 10, 90 and 64, respectively; IL-4 was < 10, < 10 and 17, respectively; and both IL-2 and IL-10 were undetectable at all three time points. ( + ) from patient 1 (top) and patient 2 (bottom) was measured by ELISA. The lower limit of sensitivity of the ELISAs was 10 pg ml -~. For those situations where cytokine release was less than 10 pg ml 1, values between 5 and 9 pg ml i were assigned to facilitate data presentation.
but one donor making both IFN-}, and IL-2 following fungal stimulation. Moreover, release of IL-4 was low or undetectable. Significant release of IL-10 was detected although, as discussed below, the IL-10 may have been derived mainly from monocytes rather than lymphocytes.
Other investigators have examined cytokine profiles in immune cells stimulated with C. neoJbrmans and C. albicans. Murphy found that spleen cells obtained from mice immunized with cryptococcal culture filtrate antigen emulsified in complete Freund adjuvant produced IL-2 and IFN-7, but not IL-4 or IL-5 [21] . Vecchiarelli et al. determined cytokine levels in supernatants of human T cells co-cultured with C. neoformans-laden alveolar macrophages [22] . IL-2, IFN-7 and IL-4 all were detected, although the levels seen averaged less than 100 pg mlAlthough direct evidence is lacking, it has been hypothesized that many cases of mucosal candidiasis in humans without apparent defects in CMI are secondary to activation of human Candida-specific TH2 type cells [23] . In experimental models of candidiasis, a T HI type response correlates with protection while a TH2 type response favours persistence of the fungus [24] [25] [26] [27] .
The data obtained with the PBMC from the patients with cryptococcosis are limited somewhat by the small number of subjects studied. Unfortunately, efforts to recruit other patients who also lacked apparent predisposing immune defects were unsuccessful. The vast majority of cryptococcosis patients seen in the 1990s have AIDS or another identifiable immunocompromising condition. Hoy et al. demonstrated that in subjects seropositive for HIV, progression to AIDS is associated with a loss of T cell proliferative responses to C. neoformans [28] . Similarly, we demonstrated that PBMC from patients with cryptococcosis and idiopathic CD4 + T lymphocytopenia do not proliferate when stimulated with C. neoformans [29] (and S. M. Levitz, unpublished results).
T and NK cells directly bind to C. neoformans and C. albicans and, under the proper conditions, mediate fungistasis [30] . Recently, we demonstrated that PBMC extensively depleted of monocytes release IFN-? (but not IL-4 and IL-10) when directly stimulated by C. neoformans and C. albicans [8] . Moreover, purified populations of both NK and T cells release IFN-7 following direct fungal stimulation. However, the amount of IFN-y released in response to fungal stimulation was considerably less than that seen in the studies reported herein using monocytereplete PBMC. Thus, while some of the IFN-7 released in response to fungal stimulation could be a result of direct stimulation of lymphocytes by the fungi, the bulk of the cytokine released appears dependent on the presence of monocytes.
In addition to lymphocytes, mononuclear phagocytes including peripheral blood monocytes are known to release IL-10. Our data do not address which cell type was responsible for IL-10 secretion when PBMC were stimulated with C. neoformans and C. albicans. The levels of IL-10 released by PBMC in response to C. neoformans were somewhat higher in the present investigation compared with previous studies from our laboratory [31] . While the reason for the disparity remains speculative, it could be related to differences in capsular size [32, 33] between the cryptococcal isolates used in the two studies as well as donor-dependent heterogeneity of response.
It is interesting to note that in PBMC from normal donors stimulated with C. neoformans, peak release of IFN-7 generally occurred during the first 1 3 days of stimulation whereas peak lymphoproliferation did not occur until day 8. In contrast, when PBMC from the two cryptococcosis patients were stimulated, IFN-7 levels were maximal on the seventh day of culture. Moreover, IL-4 was detected at two or more time points in supernatants from patient PBMC (but not control PBMC) stimulated with C. neoJormans. These data indicate that although the magnitude and kinetics of the lymphoproliferative response to whole C. neoformans is similar comparing PBMC from controls and patients, the cytokine profiles differ. Moreover, this observation, combined with the demonstration that only patient PBMC respond to soluble mannoprotein, suggest that a specific CMI response occurs following cryptococcal infection that differs from the response to C. neoJormans seen in uninfected individuals. Efforts to identify candidate antigens for cryptococcal vaccines probably should focus on antigens recognized by apparently immunocompetent persons who have recovered from cryptococcosis or healthy individuals with a history of heavy exposure to C. neoJormans [34] .
